预约演示
更新于：2025-04-12
Dobutamine Hydrochloride
盐酸多巴酚丁胺
更新于：2025-04-12
概要
基本信息
药物类型 小分子化药 |
别名 (±)-4-(2-((3-(p-hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol、3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-β-phenylethylamine、4-{2-[3-(4-Hydroxy-phenyl)-1-methyl-propylamino]-ethyl}-benzene-1,2-diol + [15] |
作用方式 激动剂 |
作用机制 adrenergic receptor激动剂(肾上腺素能受体家族激动剂) |
治疗领域 |
在研适应症 |
非在研适应症 |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24ClNO3 |
InChIKeyBQKADKWNRWCIJL-UHFFFAOYSA-N |
CAS号49745-95-1 |
关联
77
项与 盐酸多巴酚丁胺 相关的临床试验CTIS2023-504915-34-00
Dose-finding for dobutamine during transitional circulation in the very preterm infant - NeoCirc-002 TRIAL
NCT06878742
Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant
NCT06462313
Director, Head of Anesthesiology and Critical Care, Principal Investigator, Professor
100 项与 盐酸多巴酚丁胺 相关的临床结果
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的转化医学
登录后查看更多信息
100 项与 盐酸多巴酚丁胺 相关的专利（医药）
登录后查看更多信息
9,518
项与 盐酸多巴酚丁胺 相关的文献（医药）2025-04-01ANALYTICAL SCIENCES
Electron transfer-chemical reaction-electron transfer study of dobutamine, isoprenaline, droxidopa, and methyldopa with carbon nanotube-based electrode
Article
作者: Kadowaki, Mei ; Muguruma, Hitoshi ; Shu, Yoka
The electrochemical behavior of catecholamines involves an electron transfer-chemical reaction-electron transfer (ECE) mechanism, characterized by two reversible redox reactions interspersed with an irreversible chemical reaction. Previously, we reported ECE studies on dopamine and norepinephrine. In this work, we extend our study to catecholamine drugs including dobutamine, isoprenaline, droxidopa, and methyldopa, using a carbon nanotube electrode. These drugs exhibit significantly faster intramolecular cyclization rates compared to dopamine and norepinephrine. This accelerated cyclization is attributed to (1) the presence of more complex substituents in these drugs and (2) the fact that dobutamine and isoprenaline are secondary amines, while dopamine and norepinephrine are primary amines. This study enhances the understanding of catecholamines and offers valuable insights for the development of novel electrochemical sensing strategies for catecholamine drugs.
2025-04-01JOURNAL OF CRITICAL CARE
Effect of pulmonary artery catheter, type & combination of vasoactives for optimizing lactate clearance in acute myocardial infarction complicated by cardiogenic shock
Article
作者: Sierra-Lara-Martínez, Daniel ; Gopar-Nieto, Rodrigo ; Hernández-Montfort, Jaime ; Arias-Mendoza, Alexandra ; Arzate-Ramírez, Arturo ; Mendoza-García, Salvador ; Montañez-Orozco, Álvaro ; Ortega-Hernández, Jorge A ; Altamirano-Castillo, Alfredo ; García-Ruiz, Mauricio ; Baeza-Herrera, Luis Augusto ; Araiza-Garaygordobil, Diego ; Valdespino Trejo, Adrian Aquiles ; González-Pacheco, Héctor ; Manzur-Sandoval, Daniel
INTRODUCTION:
Lactate clearance(LC) is critical in managing critically ill patients. We hypothesized that treatment allocation with different vasoactive drugs or the presence of a pulmonary artery catheter (PAC) could affect the behavior of lactate dynamics and, ultimately, the mortality in AMI-CS.
MATERIALS AND METHODS:
In 651 patients with AMI-CS, we examined the relationship of LC time with clinical, laboratory, and CS-management variables. Complete LC time was defined as serum lactate levels less than <2 mmol/L. We explore the impact of vasoactive drugs and PAC with LC. The CART method defined the vasoactive combinations (permutations) in relation with early (<96 h) complete LC.
RESULTS:
PAC presence correlated with faster LC (-17.54 h) and was independently associated with lower mortality (HR = 0.61). Levosimendan and dobutamine were associated with lower lactate levels and faster LC (-8.82 & -8.77 h), while vasopressin was linked to slower LC (9.16 h). Slow LC (>96 h) was associated with increased mortality. CART analysis identified specific vasoactive drug combinations associated lactate clearance and mortality, without dobutamine, with vasopressin having higher mortality (80.6 %, HR = 5.53), and with dobutamine, with norepinephrine, without vasopressin, with levosimendan the lowest (35 %) and higher complete LC and a trend for higher %LC.
CONCLUSION:
The right combination of vasoactive medications and the probable use of a PAC could significantly impact the achievement of complete LC in <96 h. The findings support the need for further research and the development of strategies to optimize lactate clearance and improve overall patient survival in this high-risk population.
2025-04-01ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
Impact of Various Doses of Dobutamine on Myocardial Viability and the Effects of β‐Blockers in Patients With Ischemic Cardiomyopathy: An Assessment Using Stress Echocardiography
Article
作者: Li, Li ; Jiang, Zhiming ; Li, Linzi ; Li, Liangyi ; Chen, Linlin ; Yi, Na
ABSTRACT:
Background:
This study aimed to investigate the predictive value of dobutamine stress echocardiography (DSE) at varying doses for myocardial viability, with a particular emphasis on the impact of β‐adrenergic blockers on myocardial viability in patients with ischemic cardiomyopathy (ICM).
Material and Methods:
A total of 189 patients with ICM underwent DSE. Based on the dosage of dobutamine, patients were randomly divided into three groups: low‐dose group (LD, 10 µg/kg/min, n = 63), medium‐dose group (CD, 20 µg/kg/min, n = 63), and high‐dose group (HD, 30 µg/kg/min, n = 63). All patients received β‐blockers 1 min after the DSE examination. Changes in heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), radial strain (RS), and radial strain rate (RSr) during left ventricular systole (LVS) were analyzed, along with secondary effects and myocardial viability in the LD‐β, CD‐β, and HD‐β groups.
Results:
During the postoperative dobutamine injection, HR, SBP, and DBP in the LD, CD, and HD groups were significantly higher compared to pre‐injection levels (p < 0.05), with DBP in the HD group being notably higher than in the LD and CD groups (p < 0.05). After intravenous injection of metoprolol, all indicators significantly decreased in the LD and CD groups (p < 0.05). The rates of RS and RSr in the CD and HD groups were significantly lower than those in the LD group (p < 0.05). The proportion of normal wall motion viability (VWM) post‐injection was significantly higher than pre‐injection levels (p < 0.05), with the CD group surpassing the LD group (p < 0.05). The use of β‐adrenergic blockers demonstrated that the sensitivity, specificity, and accuracy of myocardial viability in the LD, CD, and HD groups were all superior to those of the control group (p < 0.05), with the CD group exhibiting the highest diagnostic performance (p < 0.05). The incidence of arrhythmias in the HD group was 20.3%, compared to 7.9% in the LD group (χ2 = 6.78, p = 0.034). Additionally, the occurrence of cardiovascular events in the HD group was 17.2%, significantly higher than the 6.3% observed in the LD group (χ2 = 6.21, p = 0.045).
Conclusion:
Moderate‐dose DSE exhibited the optimal diagnostic performance in assessing myocardial viability in patients with ICM. Furthermore, the use of β‐blockers effectively enhances the sensitivity and accuracy of the diagnosis, providing important practical guidance for the clinical evaluation of myocardial viability.
100 项与 盐酸多巴酚丁胺 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心脏衰竭 | 美国 | 1978-07-18 | |
| 脓毒性休克 | 美国 | 1978-07-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | - | (No handgrip) | 夢築鏇築蓋遞艱鏇鹹壓(選鏇蓋遞鹹餘築鹹窪壓) = 齋艱窪鏇積鬱壓壓觸簾 鏇憲積餘選鏇齋齋觸壓 (願網範獵窪鏇廠淵齋襯 ) | - | 2024-09-02 | |
(Isometric handgrip) | 夢築鏇築蓋遞艱鏇鹹壓(選鏇蓋遞鹹餘築鹹窪壓) = 製鹹鬱鹽廠獵顧艱觸鹽 鏇憲積餘選鏇齋齋觸壓 (願網範獵窪鏇廠淵齋襯 ) | ||||||
N/A | - | Adenosine infusion | 膚獵願憲選築製網鏇觸(獵網齋壓艱製襯築構膚) = 製獵繭積鹹鬱糧繭壓衊 餘鹽範齋範鏇積鹹鏇齋 (獵衊艱獵網憲觸齋壓構, 12) 更多 | - | 2024-08-31 | ||
Dobutamine infusion | 膚獵願憲選築製網鏇觸(獵網齋壓艱製襯築構膚) = 築獵範鏇餘餘鑰齋構憲 餘鹽範齋範鏇積鹹鏇齋 (獵衊艱獵網憲觸齋壓構, 13) 更多 | ||||||
N/A | - | - | 襯膚築齋鑰鬱範衊願淵(淵鹽襯餘網製鏇積願壓) = 網襯廠餘衊範鹽鏇蓋餘 積餘積齋膚廠製鹹願積 (憲糧餘積繭築膚糧網鬱, 0.27) 更多 | - | 2023-08-28 | ||
Dobutamine PET-MPI | 襯膚築齋鑰鬱範衊願淵(淵鹽襯餘網製鏇積願壓) = 積獵廠願選鏇鬱膚膚鹽 積餘積齋膚廠製鹹願積 (憲糧餘積繭築膚糧網鬱, 0.24) 更多 | ||||||
N/A | 2,328 | 觸範淵願壓齋醖衊顧齋(顧遞憲顧簾衊選繭膚網) = 窪鏇獵範醖築襯鹹壓構 窪鑰遞願餘鹽選顧壓憲 (夢簾襯繭鹹觸繭壓鹹鑰 ) 更多 | - | 2023-08-26 | |||
觸範淵願壓齋醖衊顧齋(顧遞憲顧簾衊選繭膚網) = 壓壓憲憲選觸鑰糧衊製 窪鑰遞願餘鹽選顧壓憲 (夢簾襯繭鹹觸繭壓鹹鑰 ) 更多 | |||||||
N/A | 2,881 | 製積憲膚襯襯簾夢範艱(廠衊蓋願觸鹹憲齋製鹽) = 壓鑰選鹽窪觸觸製餘淵 鏇積衊顧顧襯鹹衊壓壓 (艱膚餘鏇餘網繭獵範膚 ) 更多 | - | 2023-03-24 | |||
製積憲膚襯襯簾夢範艱(廠衊蓋願觸鹹憲齋製鹽) = 觸膚窪積顧築範鬱製積 鏇積衊顧顧襯鹹衊壓壓 (艱膚餘鏇餘網繭獵範膚 ) 更多 | |||||||
N/A | - | Insulin infusion | 鏇積選製簾鬱壓醖遞夢(餘膚繭淵衊顧築窪積簾) = 鬱簾餘範膚鏇積簾觸網 廠鏇壓夢齋餘範鏇製窪 (夢獵願構鬱範願獵選壓 ) | - | 2022-11-01 | ||
N/A | - | 遞簾顧製鏇鬱衊鑰獵範(鑰膚窪積願夢壓簾憲鏇): RR = 0.87 (95% CI, 0.79 ~ 0.97) | - | 2022-08-27 | |||
N/A | - | Dipyridamole stress PET myocardial perfusion imaging | 餘壓廠繭簾構衊醖餘壓(鏇糧廠鹹顧餘艱艱鏇蓋) = 觸廠淵積壓簾網蓋選獵 蓋鏇鬱襯淵餘繭廠夢夢 (鏇壓製壓範醖夢憲糧鑰 ) | - | 2021-05-18 | ||
Dobutamine/atropine stress PET myocardial perfusion imaging | 餘壓廠繭簾構衊醖餘壓(鏇糧廠鹹顧餘艱艱鏇蓋) = 淵築窪顧鑰觸廠鑰廠選 蓋鏇鬱襯淵餘繭廠夢夢 (鏇壓製壓範醖夢憲糧鑰 ) | ||||||
N/A | - | 膚觸鏇蓋製鹹製夢鹹鏇(夢醖鑰繭廠膚繭膚衊糧) = 顧鬱遞齋顧鹹艱鹽衊築 簾鬱糧齋鬱觸顧衊願餘 (築顧壓製餘製醖窪膚築 ) 更多 | - | 2021-05-03 | |||
N/A | - | 構築夢構構顧顧積遞廠(鏇夢襯願鏇蓋築窪選襯) = 壓襯獵網繭製齋鏇選餘 鹹襯獵鑰網網糧襯製構 (獵積築製齋糧淵壓齋蓋 ) 更多 | - | 2020-12-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用